|Bid||0.7955 x 800|
|Ask||0.8120 x 1100|
|Day's Range||0.8221 - 0.8600|
|52 Week Range||0.4500 - 1.4400|
|Beta (5Y Monthly)||1.12|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 15, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.62|
Subscribe to Yahoo Finance Plus to view Fair Value for EVGN
Here is how Compugen (CGEN) and Evogene (EVGN) have performed compared to their sector so far this year.
Lavie Bio Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products, today announced a distribution agreement exclusive to independent retail with WinField United Canada for its bio-inoculant seed treatment Yalos™. This partnership aims to support Lavie Bio's 2024 sales growth strategy in Canada, with a focus on key agricultural regions, including Saskatchewa
After losing some value lately, a hammer chart pattern has been formed for Evogene (EVGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.